We are analyzing https://link.springer.com/article/10.1007/s10495-009-0321-2.

Title:
Is TRAIL the holy grail of cancer therapy? | Apoptosis
Description:
Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

google, scholar, pubmed, article, cas, cancer, apoptosis, trail, cells, cell, death, tumor, receptor, human, necrosis, ligand, apoptosisinducing, clin, factorrelated, res, biol, trailr, antibody, therapy, dois, caspase, inhibition, oncol, phase, trailinduced, resistance, induces, receptors, monoclonal, walczak, chem, patients, study, doi, mol, protein, activation, expression, meeting, abstracts, combination, med, signaling, doijbcm, oncogene,

Topics {✒️}

tnf-related apoptosis-inducing ligand related apoptosis-inducing ligand death-inducing signaling complex histone deacetylase inhibitor nuclear factor-kappab blockade akt-mediated x-linked inhibitor month download article/chapter trail receptor-targeted therapy tnfalpha-induced nf-kappab activation combination antibody-based therapy tumour necrosis factor anti-dr5 antibody therapy based therapies death receptor-induced apoptosis smac-mimetic-induced apoptosis trail-mediated dr5-disc formation activation-induced t-cell proliferation degli-esposti ma hdac inhibitor treatment tumor-cell-derived interleukin-4 silvia prieske & henning walczak histone deacetylase receptor-mediated apoptosis induction leukemic b-lymphoid cells apoptosis-inducing protein trail-induced apoptosis mediated trail-receptor-mediated apoptosis induces cancer-specific apoptosis tnfalpha-mediated cell death trail/apo2l-induced apoptosis apo-2 ligand x-linked inhibitor induce tnfalpha-dependent apoptosis overcomes drug resistance viral flice-inhibitory proteins agonistic trail-r1 antibody nk cell-mediated killing apoptosis-resistant cholangiocarcinoma cells mitochondrial outer-membrane permeabilization recombinant human apo2l/trail sensitize tumor cells recombinant apo2l/trail versions related subjects article apoptosis aims antibody targeting trail-r1 article newsom-davis cytotoxicity-dependent apo-1 mice lacking fadd/mort1 inhibits tumor growth trail-r2/dr5 expression

Questions {❓}

Achilles’ heel of cancers?
Gores GJ, Kaufmann SH (2001) Is TRAIL hepatotoxic?
Is TRAIL the holy grail of cancer therapy?
Is TRAIL the holy grail of cancer therapy?
Wu H, Tschopp J, Lin SC (2007) Smac mimetics and TNFalpha: a dangerous liaison?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Is TRAIL the holy grail of cancer therapy?
         description:Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.
         datePublished:2009-02-05T00:00:00Z
         dateModified:2009-02-05T00:00:00Z
         pageStart:607
         pageEnd:623
         sameAs:https://doi.org/10.1007/s10495-009-0321-2
         keywords:
            TRAIL
            Apoptosis
            Cancer therapy
            TRAIL resistance
            Cancer Research
            Cell Biology
            Oncology
            Biochemistry
            general
            Virology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-009-0321-2/MediaObjects/10495_2009_321_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-009-0321-2/MediaObjects/10495_2009_321_Fig2_HTML.gif
         isPartOf:
            name:Apoptosis
            issn:
               1573-675X
               1360-8185
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Thomas Newsom-Davis
               affiliation:
                     name:Imperial College London
                     address:
                        name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Silvia Prieske
               affiliation:
                     name:Imperial College London
                     address:
                        name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Henning Walczak
               affiliation:
                     name:Imperial College London
                     address:
                        name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Is TRAIL the holy grail of cancer therapy?
      description:Inducing apoptosis has become an important approach in the development of new anti-cancer treatments. Tumour necrosis factor apoptosis inducing ligand (TRAIL) based therapies have emerged as one of the most promising examples of this as they selectively induce apoptosis in tumour cells. However, many primary tumours are inherently resistant to TRAIL-mediated apoptosis and require additional sensitisation. Here we review apoptotic and non-apoptotic TRAIL-signalling, and the therapeutic effects of TRAIL-based treatments both as monotherapy and in combination with sensitising agents.
      datePublished:2009-02-05T00:00:00Z
      dateModified:2009-02-05T00:00:00Z
      pageStart:607
      pageEnd:623
      sameAs:https://doi.org/10.1007/s10495-009-0321-2
      keywords:
         TRAIL
         Apoptosis
         Cancer therapy
         TRAIL resistance
         Cancer Research
         Cell Biology
         Oncology
         Biochemistry
         general
         Virology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-009-0321-2/MediaObjects/10495_2009_321_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-009-0321-2/MediaObjects/10495_2009_321_Fig2_HTML.gif
      isPartOf:
         name:Apoptosis
         issn:
            1573-675X
            1360-8185
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Thomas Newsom-Davis
            affiliation:
                  name:Imperial College London
                  address:
                     name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Silvia Prieske
            affiliation:
                  name:Imperial College London
                  address:
                     name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Henning Walczak
            affiliation:
                  name:Imperial College London
                  address:
                     name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Apoptosis
      issn:
         1573-675X
         1360-8185
      volumeNumber:14
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Imperial College London
      address:
         name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
         type:PostalAddress
      name:Imperial College London
      address:
         name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
         type:PostalAddress
      name:Imperial College London
      address:
         name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Thomas Newsom-Davis
      affiliation:
            name:Imperial College London
            address:
               name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
               type:PostalAddress
            type:Organization
      name:Silvia Prieske
      affiliation:
            name:Imperial College London
            address:
               name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
               type:PostalAddress
            type:Organization
      name:Henning Walczak
      affiliation:
            name:Imperial College London
            address:
               name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
      name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
      name:Tumour Immunology Unit, Department of Immunology, Imperial College London, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(609)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.45s.

LINK . SPRINGER . COM {}